Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589804576> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2589804576 endingPage "322" @default.
- W2589804576 startingPage "322" @default.
- W2589804576 abstract "322 Background: After first-line treatment with gemcitabine-based regimen, there is not standard second-line chemotherapy for patients with metastatic gallbladder cancer (GB) and cholangiocarcinoma (CC). The aim of this study was to evaluate the activity, progression free survival (PFS), and overall survival (OS) of the FOLFOX4 regimen as second-line chemotherapy. Methods: We performed a retrospective analysis of all metastatic GB and CC that were treated with gemcitabine (Gem) based first-line chemotherapy, and second-line FOLFOX4 chemotherapy (oxaliplatin 85 mg/m2, day 1; leucovorin 200 mg/m intravenously, days 1 and 2; 5-fluorouracil 400 mg/m intravenous bolus, days 1 and 2; and 600 mg/m in 22 h intravenously, continuous infusion days 1 and 2; every 14 days) in our Institution since 2003. The response rate was evaluated every 2 to 4 months according to the RECIST criteria, and PFS/OS were calculated according to the Kaplan-Meier method. Results: Eighty patients (n=40 GB; n=40 CC) received Gem based first-line treatment (42 Gem alone; 38 Gem + platinum). There was no survival difference between Gem or Gem+platinum treatment (161 versus 254 days; p=0.09). Response rate (complete and partial response) was 16% and stable disease was 31%. Ca19-9 at presentation was predictive for OS: <100U/ml =403 days versus >100 U/ml =223 days (p=0.025). Eighteen patients (22%; n=10 GB and n=8 CC) were treated with second-line FOLFOX4. In the second-line group, stable disease was achieved in 4 patients (22%), and 11 patients progressed (66%). The median DFS and OS were 96 and 138 days respectively. The median OS for patients that received one versus both lines of chemotherapy were 161 versus 400 days (p=0.009). Conclusions: FOLFOX4 has activity in second line chemotherapy for patients with metastatic GB and CC. A prospective study is warranted to confirm this observation." @default.
- W2589804576 created "2017-03-03" @default.
- W2589804576 creator A5032310022 @default.
- W2589804576 creator A5056955741 @default.
- W2589804576 creator A5061291087 @default.
- W2589804576 creator A5070646200 @default.
- W2589804576 creator A5071874168 @default.
- W2589804576 creator A5073889292 @default.
- W2589804576 creator A5083197446 @default.
- W2589804576 creator A5090203549 @default.
- W2589804576 date "2014-01-20" @default.
- W2589804576 modified "2023-10-15" @default.
- W2589804576 title "Second-line FOLFOX chemotherapy in patients with metastatic gallbladder cancer and cholangiocarcinoma." @default.
- W2589804576 doi "https://doi.org/10.1200/jco.2014.32.3_suppl.322" @default.
- W2589804576 hasPublicationYear "2014" @default.
- W2589804576 type Work @default.
- W2589804576 sameAs 2589804576 @default.
- W2589804576 citedByCount "3" @default.
- W2589804576 countsByYear W25898045762020 @default.
- W2589804576 crossrefType "journal-article" @default.
- W2589804576 hasAuthorship W2589804576A5032310022 @default.
- W2589804576 hasAuthorship W2589804576A5056955741 @default.
- W2589804576 hasAuthorship W2589804576A5061291087 @default.
- W2589804576 hasAuthorship W2589804576A5070646200 @default.
- W2589804576 hasAuthorship W2589804576A5071874168 @default.
- W2589804576 hasAuthorship W2589804576A5073889292 @default.
- W2589804576 hasAuthorship W2589804576A5083197446 @default.
- W2589804576 hasAuthorship W2589804576A5090203549 @default.
- W2589804576 hasConcept C121608353 @default.
- W2589804576 hasConcept C126322002 @default.
- W2589804576 hasConcept C141071460 @default.
- W2589804576 hasConcept C143998085 @default.
- W2589804576 hasConcept C2776694085 @default.
- W2589804576 hasConcept C2778260052 @default.
- W2589804576 hasConcept C2778336483 @default.
- W2589804576 hasConcept C2778822529 @default.
- W2589804576 hasConcept C2779984678 @default.
- W2589804576 hasConcept C2780258809 @default.
- W2589804576 hasConcept C2780962732 @default.
- W2589804576 hasConcept C2781413609 @default.
- W2589804576 hasConcept C43376680 @default.
- W2589804576 hasConcept C526805850 @default.
- W2589804576 hasConcept C71924100 @default.
- W2589804576 hasConcept C90924648 @default.
- W2589804576 hasConceptScore W2589804576C121608353 @default.
- W2589804576 hasConceptScore W2589804576C126322002 @default.
- W2589804576 hasConceptScore W2589804576C141071460 @default.
- W2589804576 hasConceptScore W2589804576C143998085 @default.
- W2589804576 hasConceptScore W2589804576C2776694085 @default.
- W2589804576 hasConceptScore W2589804576C2778260052 @default.
- W2589804576 hasConceptScore W2589804576C2778336483 @default.
- W2589804576 hasConceptScore W2589804576C2778822529 @default.
- W2589804576 hasConceptScore W2589804576C2779984678 @default.
- W2589804576 hasConceptScore W2589804576C2780258809 @default.
- W2589804576 hasConceptScore W2589804576C2780962732 @default.
- W2589804576 hasConceptScore W2589804576C2781413609 @default.
- W2589804576 hasConceptScore W2589804576C43376680 @default.
- W2589804576 hasConceptScore W2589804576C526805850 @default.
- W2589804576 hasConceptScore W2589804576C71924100 @default.
- W2589804576 hasConceptScore W2589804576C90924648 @default.
- W2589804576 hasIssue "3_suppl" @default.
- W2589804576 hasLocation W25898045761 @default.
- W2589804576 hasOpenAccess W2589804576 @default.
- W2589804576 hasPrimaryLocation W25898045761 @default.
- W2589804576 hasRelatedWork W1978714980 @default.
- W2589804576 hasRelatedWork W2091446732 @default.
- W2589804576 hasRelatedWork W2176027801 @default.
- W2589804576 hasRelatedWork W2324427928 @default.
- W2589804576 hasRelatedWork W2362472825 @default.
- W2589804576 hasRelatedWork W2371791259 @default.
- W2589804576 hasRelatedWork W2389357660 @default.
- W2589804576 hasRelatedWork W2589804576 @default.
- W2589804576 hasRelatedWork W2808934676 @default.
- W2589804576 hasRelatedWork W3180214159 @default.
- W2589804576 hasVolume "32" @default.
- W2589804576 isParatext "false" @default.
- W2589804576 isRetracted "false" @default.
- W2589804576 magId "2589804576" @default.
- W2589804576 workType "article" @default.